21 September 2018
Visiongain has launched a new pharma report: Global Acute Myeloid Leukaemia Market Report : Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib.
Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults and among the most lethal. In the United States, the annual incidence of AML is 19 000 new cases, and the incidence of AML-associated deaths is 10 000.
The rapid increase in geriatric population is one of the major drivers for the acute myeloid leukaemia market. With age, patients become highly susceptible to diseases due to decreased immunity and degeneration. As per an article published by NCBI, Acute myeloid leukaemia (AML) is the common form of acute leukaemia in adults, accounting for over 80% of all acute leukaemia in those over the age of 18 years.
The lead analyst of the report commented "The growth of the acute myeloid leukaemia market is estimated to be catalysed by opportunities in emerging markets due to improving healthcare infrastructure, unmet healthcare needs, rise in chronic diseases, and increased awareness of treatment methods.
There is a need for better therapeutics and treatment options. The increasing incidence and lack of better treatment options pose a lucrative opportunity for the market to grow and expand."
Leading companies featured in the report include Bristol-Myers Squibb Company, Celgene, Clavis Pharma ASA, Daiichi Sankyo, Eisai, GSK, Novartis, Roche, Sunesis Pharmaceuticals, Teva
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.
21 June 2022
The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.
20 June 2022
The global respiratory drug delivery technologies market was valued at US$59.51 billion in 2022 and is projected to grow at a CAGR of 7.31% during the forecast period 2022-2032.
15 June 2022
The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032.